Trial site
Tyler Retina Consultants
Tyler, Texas 75703, United StatesNot linked to an institution yet
- 7running trials
- 2closed trials
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting5 trials
- Completed2 trials
- Recruiting2 trials
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.4 trials
- 4D Molecular Therapeutics2 trials
- Oculis2 trials
- Apellis Pharmaceuticals, Inc.1 trial
Running trials
Recruiting
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
NCT07867080· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Recruiting
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
NCT07215390· Phase 2· Apellis Pharmaceuticals, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error